MP14-16 EFFICACY OF NIVOLUMAB PLUS IPILIMUMAB IN PRIMARY TUMOR AS FIRST-LINE THERAPY IN THE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP14)1 Sep 2021MP14-16 EFFICACY OF NIVOLUMAB PLUS IPILIMUMAB IN PRIMARY TUMOR AS FIRST-LINE THERAPY IN THE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Hiroshi Kikuchi, Takahiro Osawa, Ryuji Matsumoto, Takashige Abe, Satoru Maruyama, Toru Harabayashi, Haruka Miyata, Akira Kashiwagi, Ataru Sazawa, Riyo Fukui, Ken Morita, Ichiro Takeuchi, Noboru Yamashita, Keita Minami, Tango Mochizuki, and Nobuo Shinohara Hiroshi KikuchiHiroshi Kikuchi More articles by this author , Takahiro OsawaTakahiro Osawa More articles by this author , Ryuji MatsumotoRyuji Matsumoto More articles by this author , Takashige AbeTakashige Abe More articles by this author , Satoru MaruyamaSatoru Maruyama More articles by this author , Toru HarabayashiToru Harabayashi More articles by this author , Haruka MiyataHaruka Miyata More articles by this author , Akira KashiwagiAkira Kashiwagi More articles by this author , Ataru SazawaAtaru Sazawa More articles by this author , Riyo FukuiRiyo Fukui More articles by this author , Ken MoritaKen Morita More articles by this author , Ichiro TakeuchiIchiro Takeuchi More articles by this author , Noboru YamashitaNoboru Yamashita More articles by this author , Keita MinamiKeita Minami More articles by this author , Tango MochizukiTango Mochizuki More articles by this author , and Nobuo ShinoharaNobuo Shinohara More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001995.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: After the findings from CARMENA study, the role of cytoreductive nephrectomy (CN) should be considered in patient-tailored manner. Taking together with the new emergences of several effective combination therapies, the information of those effect on the primary site should be crucial for planning a future CN. This study aimed to focus exclusively on the size change of primary tumor following nivolumab plus ipilimumab (NivoIpi) treatment and elucidate the clinical factors associated with good response in primary tumor. METHODS: We retrospectively assessed 27 patients who were diagnosed with advanced renal cell carcinoma (RCC) and who had started NivoIpi. The changes in tumor size of the primary site were described using waterfall and spider plots. The parameters analyzed between responder and non-responder in the size of the primary tumor were International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk scores, peripheral blood markers and CRP. The ANOVA test was applied for the statistical analysis. RESULTS: The median age and follow-up periods were 66 years and 8.8 months, respectively. Nineteen patients were diagnosed with clear-cell renal cell carcinoma (ccRCC). Figure 1Ashow the maximum reduction from baseline in primary tumor and best overall response in ccRCC patients. Among ccRCC patients, 9 (47.4%) patients demonstrated significant response with 30% or more reduction from baseline within 4 months in primary tumors (Figure 1B). Of 6 patients who underwent nephrectomy, 3 patients whose primary tumors shrinked around 50-60% with reduction to 4 cm or less revealed no viable tumor cell in surgical specimens. Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio tended to decrease in those responders compare to non-responders among ccRCC patients (P=0.0944 and P=0.0691). Platelet-to-lymphocyte ratio significantly decreased in those responders (P=0.0391). CONCLUSIONS: In our experience, significant responses of primary tumor were obtained with NivoIpi in half cases of ccRCC. Of note, inflammation markers were possible predictive factor for treatment response of primary tumor. Although further study is needed, these observations help us to consider CN from the viewpoint of the radiological and pathological aspects. Source of Funding: None declared © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e259-e259 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hiroshi Kikuchi More articles by this author Takahiro Osawa More articles by this author Ryuji Matsumoto More articles by this author Takashige Abe More articles by this author Satoru Maruyama More articles by this author Toru Harabayashi More articles by this author Haruka Miyata More articles by this author Akira Kashiwagi More articles by this author Ataru Sazawa More articles by this author Riyo Fukui More articles by this author Ken Morita More articles by this author Ichiro Takeuchi More articles by this author Noboru Yamashita More articles by this author Keita Minami More articles by this author Tango Mochizuki More articles by this author Nobuo Shinohara More articles by this author Expand All Advertisement Loading ...